Document is current
Any future updates will be listed below
-
Authors
Bluestone, Jeffrey A. https://orcid.org/0000-0001-8793-7848
Burnett, Bruce K.
Crute, Christine E.
Fellows, Mick D.
Levings, Megan
Lebrec, Hervé
Pereira Mouriès, Lucilia https://orcid.org/0000-0001-5836-6011
Rice, Jeffrey https://orcid.org/0009-0003-1278-7621
Rohan, Patricia
Roncarolo, Maria Grazia
Rotrosen, Daniel https://orcid.org/0000-0001-5235-3850
- License Information
-
More Information
Article History
First Online: 2 June 2025
Competing interests
: The event was supported by HESI’s Cell Therapy- Tracking, Circulation and Safety (CT-TRACS) and Immunosafety committees; a grant from Genentech, a member of the Roche Group (Scientific and Research Focused Giving P-19309); as well as donations from the following sponsors: Abata Therapeutics, AbbVie, Alexandria Venture Investments, Amgen, AstraZeneca, Bristol-Myers Squibb, GentiBio, PolTREG S.A., Quell Therapeutics, Sonoma Biotherapeutics and T1D Fund. J.A.B. and H.L. are employees of Sonoma Biotherapeutics and have an equity stake in the company. M.G.R. is an employee of Tr1X and has an equity stake in the company. None of the other authors have conflicts to declare.
